Incidence and Risk Factors for Macular Atrophy in Acquired Vitelliform Lesions.

Acquired vitelliform lesions Hazard ratio Hyper-reflective foci Incidence Macular atrophy Risk factors Survival analysis

Journal

Ophthalmology. Retina
ISSN: 2468-6530
Titre abrégé: Ophthalmol Retina
Pays: United States
ID NLM: 101695048

Informations de publication

Date de publication:
03 2022
Historique:
received: 19 06 2021
revised: 17 07 2021
accepted: 30 07 2021
pubmed: 15 8 2021
medline: 6 5 2022
entrez: 14 8 2021
Statut: ppublish

Résumé

To study the time course to macular atrophy (MA) and associated risk factors in eyes with acquired vitelliform lesions (AVLs) as they vary between patients and between eyes of an individual. Single-center, retrospective, observational cohort study. Consecutive patients registered between January 2009 and January 2014 with first diagnosis of AVL confirmed by multimodal imaging were included. Eyes with baseline MA or choroidal neovascularization were excluded. Patient demographics were collected. Serial OCT scans and fundus autofluorescence (FAF) scans were graded and analyzed. Turnbull's estimator was used, and time was censored at 5 years. Multivariable Weibull parametric proportional hazard models were used to assess the association of risk factors with MA after adjustment for age and gender. Hazard ratios (HRs) are reported with 95% confidence interval (CI). Time to the first OCT evidence of MA stratified by presenting visual acuity (VA) and AVL lesion subtypes. Secondary outcome included risk factors for incident MA. A total of 237 eyes (132 patients) met the inclusion criteria. Incident MA was detected in 52 of 237 eyes (21.9%) by 5 years. Stratified by baseline VA, 40.3% of eyes with VA ≤70 letters developed atrophy within 5 years of first diagnosis in contrast to 10.3% eyes with VA >70 letters (P < 0.001). Based on lesion type only, 12.9% of eyes with vitelliform lesion at baseline developed MA versus 39.8% and 44.2% of eyes with pseudohypopyon or vitelliruptive lesion type, respectively. In adjusted analysis, baseline factors associated with increased risk of MA included VA ≤70 letters (hazard ratio [HR], 5.54; 95% confidence interval [CI], 2.30-13.34), base width (HR, 1.22; 95% CI, 1.16-1.28), maximum height (HR, 2.61; 95% CI, 1.82-3.74), presence of subretinal drusenoid deposits (SDDs) (HR, 2.83; 95% CI, 1.34-5.96), and disrupted external limiting membrane (ELM) (HR, 2.81; 95% CI, 1.34-5.86). Baseline VA of ≤70 letters (Snellen ≤20/40) and pseudohypopyon or vitelliruptive lesion type attribute the highest risk for MA. Other prognostic indicators for MA include baseline presence of SDD, disrupted ELM, and larger lesion area.

Identifiants

pubmed: 34390885
pii: S2468-6530(21)00253-0
doi: 10.1016/j.oret.2021.07.009
pii:
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

196-204

Subventions

Organisme : Medical Research Council
ID : MR/P027881/1
Pays : United Kingdom

Informations de copyright

Copyright © 2021 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Auteurs

Shruti Chandra (S)

University College London, Institute of Ophthalmology, London, United Kingdom; NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, United Kingdom.

Sarega Gurudas (S)

University College London, Institute of Ophthalmology, London, United Kingdom.

Akshay Narayan (A)

Raigmore Hospital, Inverness, United Kingdom.

Sobha Sivaprasad (S)

University College London, Institute of Ophthalmology, London, United Kingdom; NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, United Kingdom. Electronic address: sobha.sivaprasad@nhs.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH